首页 | 本学科首页   官方微博 | 高级检索  
检索        

重症肌无力患者血清补体和乙酰胆碱受体抗体的浓度变化及其相关性
引用本文:刘爱东,李柱一,林宏,宿长军,李宏增.重症肌无力患者血清补体和乙酰胆碱受体抗体的浓度变化及其相关性[J].临床神经病学杂志,2006,19(4):257-259.
作者姓名:刘爱东  李柱一  林宏  宿长军  李宏增
作者单位:710038,西安,第四军医大学唐都医院神经内科;710038,西安,第四军医大学唐都医院神经内科;710038,西安,第四军医大学唐都医院神经内科;710038,西安,第四军医大学唐都医院神经内科;710038,西安,第四军医大学唐都医院神经内科
基金项目:国家自然科学基金资助(30270485)
摘    要:目的探讨重症肌无力(MG)患者血清补体和乙酰胆碱受体抗体(AChRAb)的浓度变化及其相关性。方法对22例MG患者进行糖皮质激素规范化治疗,在治疗前、后检测其血清补体、AChRAb的浓度,并与14例非MG对照组(NC组)作对照,分析两组血清补体和AChRAb变化之间的关系。结果MG组在糖皮质激素治疗前补体C3浓度明显低于NC组(P<0.01),治疗后MG组补体C3明显增高(P<0.05),但仍低于NC组;AChRAb浓度在治疗前MG组明显高于NC组(P<0.01),治疗后MG组AChRAb浓度明显降低(P<0.05),但仍高于NC组。C5浓度MG组和NC组差异无显著性(P>0.05)。但补体(C3、C5)浓度和AChRAb浓度在治疗前(r=0.326、r=0.102,均P>0.05)和治疗后(r=0.114、r=-0.0146,均P>0.05),以及二者治疗前后变化值之间(r=-0.346、r=0.058,均P>0.05)相关性不显著。结论糖皮质激素治疗后MG患者C3浓度增加、AChRAb浓度下降,二者之间无明显相关性,补体和AChRAb在MG发病过程中可能起协同作用。

关 键 词:重症肌无力  补体  C3  C5  乙酰胆碱受体抗体
文章编号:1004-1648(2006)04-0257-03
收稿时间:2005-10-06
修稿时间:2005-11-22

Changes and correlation between the concentration of complement and titer of anti-acetylcholine receptor antibody in the sera of patients with myasthenia gravis
LIU Ai-dong, LI Zhu-yi, LIN Hong,et al..Changes and correlation between the concentration of complement and titer of anti-acetylcholine receptor antibody in the sera of patients with myasthenia gravis[J].Journal of Clinical Neurology,2006,19(4):257-259.
Authors:LIU Ai-dong  LI Zhu-yi  LIN Hong  
Institution:LIU Ai-dong, LI Zhu-yi, LIN Hong, et al.
Abstract:Objective To analyze the changes and correlation between the concentration of complement and titer of anti-acetylcholine receptor antibody (AChRAb) in the sera of patients with myastheniagravis (MG).Methods 22 MG patients were given standardize treatment with glucocorticoid. The serum concentrations of C_3, C_5 and the titer of AChRAb were detected prior and post-treatment and compared with 14 control patients without MG (NC group). The changes and correlation between concentration of complement and titer of AChRAb was analyzed.Results Prior-treatment, the concentration of C_3 was lower in MG group than in NC group ( P<0.01). Post-treatment, the concentration of C_3 was increased in MG group, but it was still lower than NC group ( P<0.05). The titer of AChRAb was higher in MG group than in NC group prior-treatment ( P<0.01), and it decreased but still higher than NC group post-treatment ( P<0.05). The difference of concentration C_5 was not significant between MG group and NC group (P>0.05). The concentration of C_3, C_5 was not correlated to the titer of AChRAb prior and post-treatment ( r=0.326, r=0.102,both P>0.05). There was also no correlation between variation of C_3, C_5 concentration and AChRAb titer prior and post-treatment ( r=-0.346, r=0.058,both P>0.05).Conclusions The serum concentration of C_3 rises and the titer of AChRAb decreases in MG patients after treatment with glucocorticoid. There is no correlation between C_3 concentration and titer of AChRAb. The complement possibly cooperates with AChRAb in pathogenesis of MG.
Keywords:myasthenia gravis  complement  C_3  C_5  anti-acetylcholine receptor antibody
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号